Compare iShares Core S&P 500 ETF (IVV) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares Core S&P 500 ETF trades at $770.54 (market cap $896.46B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: iShares Core S&P 500 ETF is far larger — about 917.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IVV | MRVI | |
|---|---|---|
Market Cap | $896.46B | $977.37M |
Volume | 4,999,099 | 2,742,564 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $9.00 |
52-Week Low | $634.93 | $2.83 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $781.42 with minimal daily movement. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. Recent news highlights mixed market sentiment with concerns about profit growth deceleration but optimism for year-end rallies. The ETF maintains its core position as a broad market exposure vehicle with consistent dividend distributions.
The outlook remains cautiously optimistic given the S&P 500's strong institutional support and historical performance. Key opportunities include potential year-end momentum and AI-driven growth in top holdings. Risks center on valuation concerns, profit growth slowdown projections, and market concentration in technology stocks that could amplify volatility during corrections.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
